Arbutus Biopharma (ABUS) Payables (2010 - 2026)
Arbutus Biopharma (ABUS) posted Payables of $4.5 million for Q1 2026, down 18.04% sequentially from $5.5 million in Q4 2025, and down 63.05% YoY from $12.1 million in Q1 2025.
Arbutus Biopharma (ABUS) Payables (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Payables for 17 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Payables fell 63.05% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 63.05% YoY) and the FY2025 annual result came in at $5.5 million, down 27.83% from the prior year.
- Payables retreated to $4.5 million in Q1 2026 per ABUS's latest filing, from $5.5 million in the prior quarter.
- Over five years, Payables peaked at $16.0 million in Q4 2022 and troughed at $4.5 million in Q1 2026.
- A 5-year average of $9.0 million and a median of $8.8 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2026: Payables surged 49.35% in 2022, then slumped 63.05% in 2026.
- Over 5 years, Payables stood at $16.0 million in 2022, then tumbled by 35.92% to $10.3 million in 2023, then dropped by 26.36% to $7.6 million in 2024, then dropped by 27.83% to $5.5 million in 2025, then decreased by 18.04% to $4.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $4.5 million, $5.5 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 2.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.85 Mn |
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 5.46 Mn |
| Sep 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 4.51 Mn |
| Mar 31, 2025 | 12.11 Mn |
| Dec 31, 2024 | 7.56 Mn |
| Sep 30, 2024 | 7.54 Mn |
| Jun 30, 2024 | 11.11 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | 10.27 Mn |
| Sep 30, 2023 | 9.81 Mn |
| Jun 30, 2023 | 8.81 Mn |
| Mar 31, 2023 | 9.65 Mn |
| Dec 31, 2022 | 16.03 Mn |
| Sep 30, 2022 | 12.27 Mn |
| Jun 30, 2022 | 12.47 Mn |
| Mar 31, 2022 | 8.72 Mn |
| Dec 31, 2021 | 10.84 Mn |
| Sep 30, 2021 | 9.73 Mn |